Anti-Helicobacter pylori actions of CV-6209, a platelet-activating factor receptor antagonist

Journal of General and Applied Microbiology

Volumn 59, Issue 2, 2013, Pages 147-152

  Iwao, Yasuhisa ^a   Takano, Tomomi ^a   Taneike, Ikue ^a   Reva, Ivan ^a   Isobe, Hirokazu ^a   Zhang, Hui Min ^b   Nishiyama, Akihito ^a   Yamamoto, Tatsuo ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b SHANGHAI UNIVERSITY   (China)

Author keywords

Cellular ATP; CV 6209; Growth; Helicobacter pylori; Morphology; Motility; Platelet activating factor (PAF) receptor antagonist

Indexed keywords

2 [N (2 METHOXY 3 OCTADECYLCARBAMOYLOXYPROPOXYCARBONYL)ACETAMIDOMETHYL] 1 ETHYLPYRIDINIUM CHLORIDE; [2 METHOXY 3 (N OCTADECYLCARBAMOYLOXY)PROPYL] (2 THIAZOLIOETHYL) PHOSPHATE; AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; CAMPYLOBACTER; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; ESCHERICHIA COLI; HELICOBACTER PYLORI; IC 50; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPECIES COMPARISON; VIBRIO;

ADENOSINE TRIPHOSPHATE; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; HELICOBACTER PYLORI; LOCOMOTION; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MICROSCOPY, ELECTRON, SCANNING; PLATELET MEMBRANE GLYCOPROTEINS; PYRIDINIUM COMPOUNDS; RECEPTORS, G-PROTEIN-COUPLED;

HELICOBACTER PYLORI;

EID: 84878839833     PISSN: 00221260     EISSN: 13498037     Source Type: Journal    
DOI: 10.2323/jgam.59.147     Document Type: Article

References (26)

1. Andersen, L. P. and Rasmussen, L. (2009) Helicobacter pyloricoccoid forms and biofilm formation. FEMS. Immunol. Med. Microbiol., 56, 112-115.
2. Asaka, M., Kato, M., Takahashi, S., Fukuda, Y., Sugiyama, T., Ota, H., Uemura, N., Murakami, K., Satoh, K., and Sugano, K. (2010) Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter, 15, 1-20.
3. Atherton, J. C. and Blaser, M. J. (2009) Coadaptation of Helicobacter pylori and humans: Ancient history, modern implications. J. Clin. Invest., 119, 2475-2487.
4. Bonis, M., Ecobichon, C., Guadagnini, S., Prevost, M. C., and Boneca, I. G. (2010) A M23B family metallopeptidase of Helicobacter pylori required for cell shape, pole formation and virulence. Mol. Microbiol., 78, 809-819.
5. Clinical and Laboratory Standards Institute (CLSI) (2011) Performance standards for antimicrobial susceptibility testing: 18th informational supplement M100-S21. CLSI, Wayne, PA.
6. De Francesco, V., Giorgio, F., Hassan, C., Manes, G., Vannella, L., Panella, C., Ierardi, E., and Zullo, A. (2010) Worldwide H. pylori antibiotic resistance: A systematic review. J. Gastrointestin. Liver Dis., 19, 409-414.
7. DeLoney, C. R. and Schiller, N. L. (1999) Competition of various beta-lactam antibiotics for the major penicillin-binding proteins of Helicobacter pylori: Antibacterial activity and effects on bacterial morphology. Antimicrob. Agents Chemother., 43, 2702-2709.
8. Denizot, Y., Dassa, E., Kim, H. Y., Bossant, M. J., Salem, N., Jr., Thomas, Y., and Benveniste, J. (1989) Synthesis of pafacether from exogenous precursors by the prokaryote Escherichia coli. FEBS Lett., 243, 13-16.
9. Denizot, Y., Sobhani, I., Rambaud, J. C., Lewin, M., Thomas, Y., and Benveniste, J. (1990) Paf-acether synthesis by Helicobacter pylori. Gut, 31, 1242-1245.
10. Eaton, K. A., Morgan, D. R., and Krakowka, S. (1992) Motility as a factor in the colonisation of gnotobiotic piglets by Helicobacter pylori. J. Med. Microbiol., 37, 123-127.
11. Gasbarrini, A., Franceschi, F., Tartaglione, R., Landolfi, R., Pola, P., and Gasbarrini, G. (1998) Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet, 352, 878.
12. Gerrits, M. M., van Vliet, A. H., Kuipers, E. J., and Kusters, J. G. (2006) Helicobacter pylori and antimicrobial resistance: Molecular mechanisms and clinical implications. Lancet Infect. Dis., 6, 699-709.
13. Gluck, M. R., Krueger, M. J., Ramsay, R. R., Sablin, S. O., Singer, T. P., and Nicklas, W. J. (1994) Characterization of the inhibitory mechanism of 1-methyl-4-phenylpyridinium and 4-phenylpyridine analogs in inner membrane preparations. J. Biol. Chem., 269, 3167-3174.
14. Graham, D. Y. and Fischbach, L. (2010) Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut, 59, 1143-1153.
15. Malfertheiner, P., Megraud, F., O'Morain, C., Bazzoli, F., El-Omar, E., Graham, D., Hunt, R., Rokkas, T., Vakil, N., and Kuipers, E. J. (2007) Current concepts in the management of Helicobacter pylori infection: The Maastricht III Consensus Report. Gut, 56, 772-781.
16. Mizoguchi, H., Fujioka, T., Kishi, K., Nishizono, A., Kodama, R., and Nasu, M. (1998) Diversity in protein synthesis and viability of Helicobacter pylori coccoid forms in response to various stimuli. Infect. Immun., 66, 5555-5560.
17. Nagata, K., Sone, N., and Tamura, T. (2001) Inhibitory activities of lansoprazole against respiration in Helicobacter pylori. Antimicrob. Agents Chemother., 45, 1522-1527.
18. Negrini, R., Savio, A., Poiesi, C., Appelmelk, B. J., Buffoli, F., Paterlini, A., Cesari, P., Graffeo, M., Vaira, D., and Franzin, G. (1996) Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology, 111, 655-665.
19. Shen, Y., Sultana, C., Arditi, M., Kim, K. S., and Kalra, V. K. (1998) Endotoxin-induced migration of monocytes and PECAM-1 phosphorylation are abrogated by PAF receptor antagonists. Am. J. Physiol., 275, E479-486.
20. Shirai, M., Kakada, J., Shibata, K., Morshed, M. G., Matsushita, T., and Nakazawa, T. (2000) Accumulation of polyphosphate granules in Helicobacter pylori cells under anaerobic conditions. J. Med. Microbiol., 49, 513-519.
21. Taneike, I., Tamura, Y., Shimizu, T., Yamashiro, Y., and Yamamoto, T. (2001) Helicobacter pylori intrafamilial infections: Change in source of infection of a child from father to mother after eradication therapy. Clin. Diagn. Lab. Immunol., 8, 731-739.
22. Tashiro, H., Miura, S., Kurose, I., Fukumura, D., Suzuki, H., Suematsu, M., Yoshioka, M., Tsuchiya, M., Kai, A., and Kudoh, Y. (1994) Verotoxin induces hemorrhagic lesions in rat small intestine. Temporal alteration of vasoactive substances. Dig. Dis. Sci., 39, 1230-1238.
23. Terashita, Z., Imura, Y., Takatani, M., Tsushima, S., and Nishikawa, K. (1987) CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J. Pharmacol. Exp. Ther., 242, 263-268.
24. Tsutsui, N., Taneike, I., Ohara, T., Goshi, S., Kojio, S., Iwakura, N., Matsumaru, H., Wakisaka-Saito, N., Zhang, H. M., and Yamamoto, T. (2000) A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori. Antimicrob. Agents Chemother., 44, 3069-3073.
25. Yoshikawa, T., Takahashi, S., Naito, Y., Ueda, S., Tanigawa, T., Yoshida, N., and Kondo, M. (1992) Effects of a platelet-activating factor antagonist, CV-6209, on gastric mucosal lesions induced by ischemia-reperfusion. Lipids, 27, 1058-1060.
26. Zhang, H. M., Ohmura, M., Gondaira, F., and Yamamoto, T. (2001) Inhibition of Shiga toxin-induced tumor necrosis factor-alpha production and gene expression in human monocytic cells by CV6209. Life Sci., 68, 1931-1937.